Ramipril Alleviates Oxaliplatin-Induced Acute Pain Syndrome in Mice.
cold allodynia
mechanical allodynia
neuropathic pain
oxaliplatin
ramipril
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
05
2021
accepted:
25
06
2021
entrez:
5
8
2021
pubmed:
6
8
2021
medline:
6
8
2021
Statut:
epublish
Résumé
Oxaliplatin is a key drug for colorectal cancer that causes OXP-induced peripheral neuropathy, a dose-limiting effect characterized by cold and tactile hyperesthesia. The relationship between the sensory nervous system and modulation of the renin-angiotensin system has been described, focusing on pain and neurodegeneration in several animal models. We assessed the effect of the RAS modulator, ramipril, an angiotensin converting-enzyme inhibitor in a mouse model of OXP-induced acute pain syndrome. OXP was administered in Swiss mice at a cumulative dose of 15 mg/kg (3 x 5 mg/kg/3 days, i.p.). RAM was administered i.p. every day from 24 h before the first OXP injection until the end of the experiments. We evaluated OIAS development and treatment effects by sensorimotor tests, intraepidermal nerve fiber and dorsal root ganglia-neuron immunohistochemical analyses, and sciatic nerve ultrastructural analysis. OXP-treated mice showed tactile allodynia and cold hypersensitivity, without motor impairment and evidence of nerve degeneration. RAM prevented cold sensitivity and improved recovery of normal tactile sensitivity in OXP-treated mice. Our finding that RAM alleviates OXP-induced pain is a step towards evaluating its therapeutic potential in patients receiving OXP treatment.
Identifiants
pubmed: 34349658
doi: 10.3389/fphar.2021.712442
pii: 712442
pmc: PMC8326755
doi:
Types de publication
Journal Article
Langues
eng
Pagination
712442Informations de copyright
Copyright © 2021 Bouchenaki, Danigo, Bernard, Bessaguet, Richard, Sturtz, Balayssac, Magy and Demiot.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
EMBO Mol Med. 2011 May;3(5):266-78
pubmed: 21438154
Int J Neurosci. 2015 Jun;125(6):464-73
pubmed: 25069044
Pharmaceuticals (Basel). 2021 Feb 24;14(3):
pubmed: 33668331
Cell Mol Neurobiol. 2013 Jul;33(5):681-8
pubmed: 23564180
Biol Pharm Bull. 2020 Feb 1;43(2):348-355
pubmed: 31776306
Int J Mol Sci. 2020 Jan 27;21(3):
pubmed: 32012798
Mol Pain. 2014 Apr 16;10:26
pubmed: 24739328
Eur J Neurol. 2005 Oct;12(10):747-58
pubmed: 16190912
Neuropharmacology. 2017 Nov;126:142-150
pubmed: 28882562
J Pharmacol Sci. 2014;124(4):514-7
pubmed: 24671055
Eur J Pain. 2019 Apr;23(4):739-749
pubmed: 30421564
Clin Ther. 2018 Jul;40(7):1214-1222.e1
pubmed: 29983264
Pain Physician. 2017 May;20(4):281-292
pubmed: 28535551
J Clin Oncol. 2009 Mar 10;27(8):1243-9
pubmed: 19164207
Mol Pain. 2012 Jan 31;8:7
pubmed: 22292988
J Clin Med. 2020 Jul 27;9(8):
pubmed: 32727095
Pain. 2018 Dec;159(12):2538-2546
pubmed: 30086116
J Pain. 2012 Mar;13(3):276-84
pubmed: 22325298
Mol Pain. 2009 Feb 26;5:9
pubmed: 19245717
Expert Rev Neurother. 2016;16(3):331-9
pubmed: 26852820
Ann Neurol. 2017 Jun;81(6):772-781
pubmed: 28486769
Pain. 2011 Jul;152(7):1621-1631
pubmed: 21481532
PLoS One. 2011 Apr 08;6(4):e18469
pubmed: 21494615
Curr Opin Support Palliat Care. 2016 Jun;10(2):119-128
pubmed: 27054288
Obesity (Silver Spring). 2008 Jan;16(1):82-9
pubmed: 18223617
Exp Neurol. 2011 Jun;229(2):353-7
pubmed: 21385581
J Exp Med. 1998 Aug 17;188(4):661-70
pubmed: 9705948
J Renin Angiotensin Aldosterone Syst. 2015 Mar;16(1):103-12
pubmed: 25487978
Eur J Cancer. 2007 Dec;43(18):2658-63
pubmed: 17855072
Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11199-204
pubmed: 23776246
J Pharmacol Exp Ther. 2014 Sep;350(3):635-45
pubmed: 24990940
J Pain. 2021 Mar 24;:
pubmed: 33774154
Brain Res Mol Brain Res. 1998 Jun 1;57(1):111-22
pubmed: 9630555
Mol Neurobiol. 2021 Jul;58(7):3575-3587
pubmed: 33772465
Nitric Oxide. 2014 Feb 15;37:11-6
pubmed: 24361899
Regul Pept. 2010 Jun 8;162(1-3):90-8
pubmed: 20346377
Exp Neurol. 1996 Mar;138(1):93-104
pubmed: 8593900
Pain. 2016 Dec;157(12):2709-2721
pubmed: 27541850
J Neurophysiol. 2001 May;85(5):2293-7
pubmed: 11353042
Mol Neurobiol. 2019 Nov;56(11):7408-7419
pubmed: 31037647
J Clin Oncol. 2015 Oct 20;33(30):3416-22
pubmed: 26282635
J Clin Oncol. 2020 Oct 1;38(28):3325-3348
pubmed: 32663120
Neuroscience. 2012 Feb 17;203:194-206
pubmed: 22200546
Neurology. 2017 Aug 22;89(8):859-869
pubmed: 28747442
Front Mol Biosci. 2020 May 20;7:96
pubmed: 32528973
Brain Res. 1986 Feb 5;364(2):233-40
pubmed: 3947969
J Neurosci. 2005 Mar 2;25(9):2405-12
pubmed: 15745967
Cancer Treat Rev. 2008 Jun;34(4):368-77
pubmed: 18281158
Anticancer Res. 2011 Dec;31(12):4413-6
pubmed: 22199308
Mol Pain. 2013 Oct 23;9:53
pubmed: 24152430
Brain Res. 2011 Apr 28;1387:8-18
pubmed: 21376708
Cancer Chemother Pharmacol. 2005 Oct;56(4):391-9
pubmed: 15887017
Ann Oncol. 2020 Oct;31(10):1306-1319
pubmed: 32739407
Free Radic Biol Med. 2020 Dec;161:246-262
pubmed: 32980538
Mol Pain. 2011 Apr 26;7:29
pubmed: 21521528
Cancer Chemother Pharmacol. 2008 Nov;62(6):995-1007
pubmed: 18270703
Anesthesiology. 2014 Feb;120(2):459-73
pubmed: 24064792
Mol Pain. 2012 Jul 28;8:55
pubmed: 22839205
Am J Hypertens. 1999 Dec;12(12 Pt 3):189S-194S
pubmed: 10619571
PLoS Biol. 2020 Jul 14;18(7):e3000411
pubmed: 32663221
Crit Rev Oncol Hematol. 2006 Aug;59(2):159-68
pubmed: 16806962